Madrid, Spain

Dirk Buescher

USPTO Granted Patents = 2 

 

 

Average Co-Inventor Count = 2.4

ph-index = 1


Company Filing History:


Years Active: 2015-2018

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Dirk Buescher: Innovator in Immunomodulatory Cell Research

Introduction

Dirk Buescher is a prominent inventor based in Madrid, Spain. He has made significant contributions to the field of immunology, particularly in the development of immunomodulatory cells. With a total of 2 patents, his work has the potential to impact the treatment of various diseases.

Latest Patents

Dirk Buescher's latest patents include innovative methods for the preparation and use of immunomodulatory cells. One patent describes a method for generating these cells by contacting a mesenchymal stem cell (MSC) and/or fibroblast cell population with peripheral blood leukocytes for a duration ranging from about 2 hours to about 25 days. Another patent focuses on cells capable of expressing IDO, along with nucleic acid constructs for the expression of IDO. This invention emphasizes the use of cells that can express IDO without exposure to IFN-gamma, which is crucial for the preparation of antigen-specific immunomodulatory cells.

Career Highlights

Throughout his career, Dirk Buescher has worked with notable companies in the biotechnology sector, including Cellerix, S.A. and Tigenix, S.A. His experience in these organizations has allowed him to advance his research and contribute to the development of innovative therapies.

Collaborations

Dirk has collaborated with esteemed colleagues such as Olga De La Rosa and Eleuterio Lombardo. These partnerships have fostered a collaborative environment that enhances the research and development of immunomodulatory therapies.

Conclusion

Dirk Buescher is a key figure in the field of immunology, with a focus on the development of immunomodulatory cells. His patents and collaborations reflect his commitment to advancing medical science and improving treatment options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…